GlassScriptPhysician profile
Suma Satti
NPI 1861683906
$339,918.95
in general payments reported to CMS, 2019-2025
28 companies · $36K in 2025
The $36K reported for 2025 was more than what 91% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $28K · 2021: $46K · 2022: $48K · 2023: $67K · 2024: $51K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $134K · Consulting Fee: $11K · Food and Beverage: $3,497 · Travel and Lodging: $3,222 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,275 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $134,019.50 |
| Consulting Fee | $11,457.50 |
| Food and Beverage | $3,497.37 |
| Travel and Lodging | $3,222.09 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,275.00 |
| Education | $194.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $171,114.46 | 2019-2025 | Imfinzi, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $53,247.95 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $35,872.19 | 2019-2022 | |
| Eisai INC. | $29,326.22 | 2019-2023 | |
| Janssen Biotech, INC. | $21,417.36 | 2022-2025 | Rybrevant |
| Mirati Therapeutics, INC. | $12,276.14 | 2023 | Krazati |
| Genzyme Corporation | $7,260.38 | 2019 | |
| Novocure INC. | $2,600.00 | 2024-2025 | Optune Lua (Novottf-200t) |
| Deciphera Pharmaceuticals INC. | $1,900.00 | 2021 | |
| Bristol Myers Squibb Company | $1,650.00 | 2023 | |
| Genentech USA, INC. | $1,011.05 | 2019-2023 | Tecentriq, Alecensa |
| Bayer Healthcare Pharmaceuticals INC. | $1,000.00 | 2021 | |
| Celgene Corporation | $300.00 | 2022 | |
| Intuitive Surgical, INC. | $273.47 | 2022 | |
| Daiichi Sankyo INC. | $153.57 | 2024-2025 | Enhertu, Datroway |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $127.44 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $99.00 | 2025 | Onivyde |
| Incyte Corporation | $95.21 | 2021 | |
| Abbvie INC. | $81.57 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $70.00 | 2023-2024 | Fotivda |
| Tempus Ai, INC | $18.24 | 2024 | |
| Taiho Oncology, INC. | $12.78 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suma Satti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.